How does prior BCG vaccination affect the interpretation of a tuberculin skin test (TST)?

BCG Vaccination Causes False-Positive TST Results

Prior BCG vaccination reduces TST specificity by causing false-positive reactions through cross-reactivity with mycobacterial antigens, with the magnitude and duration of this effect depending critically on the age at vaccination and number of doses administered.

Key Determinants of BCG Impact on TST

The effect of BCG on TST interpretation is not uniform—it varies substantially based on several factors 1, 2:

Age at Vaccination (Most Critical Factor)

• BCG given in infancy: Only 8.5% show false-positive TST ≥10mm, and this drops to just 1% if tested ≥10 years post-vaccination 3
• BCG given after infancy: 41.8% show false-positive TST ≥10mm, with 21.2% remaining positive even after 10 years 3
• Neonatal BCG: Minimal impact after 10 months of age, with no reactions >5mm observed after this timepoint in children without TB contact 4

Duration Since Vaccination

Contrary to conventional CDC teaching that BCG effects wane after 10 years, BCG vaccination after infancy can influence TST results for up to 55 years post-vaccination 5. The adjusted hazard ratio for TST positivity remains elevated at 1.26 even 16-55 years after vaccination 5.

Number of Doses

Multiple BCG vaccinations significantly increase false-positive rates 1. Recent meta-analysis confirms that number of doses is a significant modifier of false positivity 6.

Practical Interpretation Algorithm

For BCG-vaccinated individuals, use this approach:

1. If vaccinated as infant (0-12 months): Interpret TST normally using standard cutoffs—BCG effect is minimal, especially if >10 years since vaccination 3

2. If vaccinated after infancy or multiple doses:

   • TST reactions >20mm are unlikely due to BCG alone and should be considered true infection 2
   • TST reactions 10-19mm have poor specificity (PPV only 51.6-65%) 7
   • Strongly consider IGRA testing instead to avoid false-positives 1, 8

3. In immunosuppressed/HIV patients: BCG-vaccinated individuals show significantly higher false-positive TST rates (33.3% vs 11.3% in unvaccinated), but IGRAs are not affected by BCG status 8. Use IGRA preferentially in this population.

Geographic and Epidemiologic Modifiers

False-positivity from BCG decreases with:

• Increasing TB incidence in the region 6
• Increasing latitude 6

This means BCG has greater impact on TST specificity in low-incidence, low-latitude settings where the test is already less useful due to low positive predictive value.

Common Pitfalls to Avoid

Do not dismiss positive TST solely based on BCG history 2. The guideline explicitly states "no reliable method has been developed to distinguish tuberculin reactions caused by vaccination with BCG from those caused by natural mycobacterial infections" 2.

Do not assume BCG effects disappear after 10 years if vaccination occurred after infancy—this conventional teaching is contradicted by long-term follow-up data 5.

Do not use the same interpretation threshold for all BCG-vaccinated individuals—age at vaccination fundamentally changes the clinical significance 3.

When to Use IGRA Instead

IGRA should be preferred over TST in BCG-vaccinated individuals when 1, 6:

• Vaccinated after infancy
• Multiple BCG doses received
• Low TB incidence setting
• Immunosuppressed patients
• Need for serial testing (healthcare workers, etc.)

IGRAs use antigens (ESAT-6, CFP-10) absent from all BCG strains, providing superior specificity in vaccinated populations 1.